Clinical trial NCT05002647: Relationship Between the Clinical Pharmacist & Antibiotic Use by Using the Electronic Program
Official title: Relationship Between the Clinical Pharmacist & Antibiotic Use in Selected Infectious Disease Hospitals in El Beheira by Using the Electronic Program, Retrospective Cohort
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Clinical Pharmacists
Electronic Medical Record
Keywords: clinical pharmacist
antibiotic consumption
antibiotic use
cost-saving
Lead sponsor: Alexandria University
Sponsor class: OTHER
Collaborators: name: Ministry of Health and Population, Egypt
First posted: 2021-08-12
Enrollment: 2601
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients who administered antimicrobials

Brief summary: A retrospective cohort study to explore the association between clinical pharmacists' interventions and antibiotic consumption through the use of the medical electronic reports and to identify mortality and cost savings in hospital infectious disease.

Detailed description: The role of clinical pharmacist includes :

1. a check of suitable selection and dosing of antimicrobials according to the diagnosis, type of infection, antimicrobial cultures as possible, comorbidities of patients (renal or hepatic function, etc), adverse effect, and drug interaction with other drugs.
2. Documentation of the clinical intervention, cost-saving, adverse effect,, antimicrobial culture and antimicrobial consumption on the electronic program (CPC "clinical patient care").
3. The clinical pharmacist inspector reviews the data recorded on CPC.

Eligibility criteria: Inclusion Criteria:

* All inpatient with infectious disease (disorders caused by organisms as (bacteria, viruses, fungi, or parasites).

Exclusion Criteria:

* Any other cause of hospital admission other than infectious disease.

Primary outcomes:
measure: Antimicrobial consumption
timeFrame: 2 years
measure: Days of therapy (DOT)
timeFrame: 2 years
measure: Length of therapy(LOT)
timeFrame: 2 years
Secondary outcomes:
measure: cost savings
timeFrame: 2 years
measure: Mortality rate
timeFrame: 2 years
measure: Antimicrobial resistance
timeFrame: 2 years
measure: The incidence of adverse reaction of antimicrobial
timeFrame: 2 years
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Ministers of health
Study officials:
affiliation: Ministry of Health and Population, Egypt
name: Amira zidane
role: PRINCIPAL_INVESTIGATOR
References:
citation: Karakonstantis S, Kalemaki D. Antimicrobial overuse and misuse in the community in Greece and link to antimicrobial resistance using methicillin-resistant S. aureus as an example. J Infect Public Health. 2019 Jul-Aug;12(4):460-464. doi: 10.1016/j.jiph.2019.03.017. Epub 2019 Apr 10.
citation: Dyar OJ, Huttner B, Schouten J, Pulcini C; ESGAP (ESCMID Study Group for Antimicrobial stewardshiP). What is antimicrobial stewardship? Clin Microbiol Infect. 2017 Nov;23(11):793-798. doi: 10.1016/j.cmi.2017.08.026. Epub 2017 Sep 4.
citation: Ourghanlian C, Lapidus N, Antignac M, Fernandez C, Dumartin C, Hindlet P. Pharmacists' role in antimicrobial stewardship and relationship with antibiotic consumption in hospitals: An observational multicentre study. J Glob Antimicrob Resist. 2020 Mar;20:131-134. doi: 10.1016/j.jgar.2019.07.009. Epub 2019 Jul 16.